These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma. Newton DL; Hansen HJ; Mikulski SM; Goldenberg DM; Rybak SM Blood; 2001 Jan; 97(2):528-35. PubMed ID: 11154233 [TBL] [Abstract][Full Text] [Related]
5. Antibody-targeted RNase fusion proteins (immunoRNases) for cancer therapy. Krauss J; Arndt MA; Dübel S; Rybak SM Curr Pharm Biotechnol; 2008 Jun; 9(3):231-4. PubMed ID: 18673289 [TBL] [Abstract][Full Text] [Related]
6. [Onconase: a ribonuclease with antitumor activity]. Zwolińska M; Smolewski P Postepy Hig Med Dosw (Online); 2010 Feb; 64():58-66. PubMed ID: 20173221 [TBL] [Abstract][Full Text] [Related]
7. Ribonucleases as potential modalities in anticancer therapy. Ardelt W; Ardelt B; Darzynkiewicz Z Eur J Pharmacol; 2009 Dec; 625(1-3):181-9. PubMed ID: 19825371 [TBL] [Abstract][Full Text] [Related]
8. Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes. Ardelt W; Shogen K; Darzynkiewicz Z Curr Pharm Biotechnol; 2008 Jun; 9(3):215-25. PubMed ID: 18673287 [TBL] [Abstract][Full Text] [Related]
9. Onconase mediated NFKβ downregulation in malignant pleural mesothelioma. Goparaju CM; Blasberg JD; Volinia S; Palatini J; Ivanov S; Donington JS; Croce C; Carbone M; Yang H; Pass HI Oncogene; 2011 Jun; 30(24):2767-77. PubMed ID: 21317924 [TBL] [Abstract][Full Text] [Related]
11. Intracellular pathway of Onconase that enables its delivery to the cytosol. Rodríguez M; Torrent G; Bosch M; Rayne F; Dubremetz JF; Ribó M; Benito A; Vilanova M; Beaumelle B J Cell Sci; 2007 Apr; 120(Pt 8):1405-11. PubMed ID: 17374640 [TBL] [Abstract][Full Text] [Related]
12. Sustained and cancer cell targeted cytosolic delivery of Onconase results in potent antitumor effects. Zhao HL; Xue C; Du JL; Ren M; Xia S; Cheng YG; Liu ZM J Control Release; 2012 May; 159(3):346-52. PubMed ID: 22715504 [TBL] [Abstract][Full Text] [Related]
14. Onconase responsive genes in human mesothelioma cells: implications for an RNA damaging therapeutic agent. Altomare DA; Rybak SM; Pei J; Maizel JV; Cheung M; Testa JR; Shogen K BMC Cancer; 2010 Feb; 10():34. PubMed ID: 20137089 [TBL] [Abstract][Full Text] [Related]
15. Role of the N terminus in RNase A homologues: differences in catalytic activity, ribonuclease inhibitor interaction and cytotoxicity. Boix E; Wu Y; Vasandani VM; Saxena SK; Ardelt W; Ladner J; Youle RJ J Mol Biol; 1996 Apr; 257(5):992-1007. PubMed ID: 8632481 [TBL] [Abstract][Full Text] [Related]
16. Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease. Rybak SM; Pearson JW; Fogler WE; Volker K; Spence SE; Newton DL; Mikulski SM; Ardelt W; Riggs CW; Kung HF; Longo DL J Natl Cancer Inst; 1996 Jun; 88(11):747-53. PubMed ID: 8637029 [TBL] [Abstract][Full Text] [Related]
17. Cancer chemotherapy--ribonucleases to the rescue. Leland PA; Raines RT Chem Biol; 2001 May; 8(5):405-13. PubMed ID: 11358688 [TBL] [Abstract][Full Text] [Related]
18. Activating transcription factor 3 is crucial for antitumor activity and to strengthen the antiviral properties of Onconase. Vert A; Castro J; Ribó M; Benito A; Vilanova M Oncotarget; 2017 Feb; 8(7):11692-11707. PubMed ID: 28035074 [TBL] [Abstract][Full Text] [Related]
19. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Shor B; Gerber HP; Sapra P Mol Immunol; 2015 Oct; 67(2 Pt A):107-16. PubMed ID: 25304309 [TBL] [Abstract][Full Text] [Related]
20. Constitutive expression and anticancer potency of a novel immunotoxin onconase-DV3. Sun M; Tang H; Gao Y; Dai X; Yuan Y; Zhang C; Sun D Oncol Rep; 2016 Apr; 35(4):1987-94. PubMed ID: 26782924 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]